Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)

Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)

Abstract Background To evaluate patient-reported outcomes with ramucirumab plus docetaxel, a regimen which improved progression-free survival in platinum-refractory advanced urothelial carcinoma (aUC). Methods RANGE—a randomized, double-blinded, phase 3 trial in patients with platinum-refractory aUC...

Full description

Bibliographic Details
Main Authors: Andrea Necchi, Hiroyuki Nishiyama, Nobuaki Matsubara, Jae-Lyun Lee, Daniel P. Petrylak, Ronald de Wit, Alexandra Drakaki, Astra M. Liepa, Huzhang Mao, Katherine Bell-McGuinn, Thomas Powles
Format: Article
Language:English
Published: BMC 2020-11-01
Series:BMC Urology
Subjects:
Antiangiogenesis
Bladder cancer
Neoplasm metastatsis
Patient-reported outcomes
Quality of life
Ramucirumab
Online Access:http://link.springer.com/article/10.1186/s12894-020-00752-w

Internet

http://link.springer.com/article/10.1186/s12894-020-00752-w

Similar Items